Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice

Benjamin Assouline,Rachel Kahn,Lutfi Hodali,Reba Condiotti,Yarden Engel,Ela Elyada,Tzlil Mordechai-Heyn,Jason R Pitarresi,Dikla Atias,Eliana Steinberg,Tirza Bidany-Mizrahi,Esther Forkosh,Lior H Katz,Ofra Benny,Talia Golan,Matan Hofree,Sheila A Stewart,Karine A Atlan,Gideon Zamir,Ben Z Stanger,Michael Berger,Ittai Ben-Porath

DOI: https://doi.org/10.1038/s41467-024-50441-7

2024-07-22

Abstract:Senescent cells within tumors and their stroma exert complex pro- and anti-tumorigenic functions. However, the identities and traits of these cells, and the potential for improving cancer therapy through their targeting, remain poorly characterized. Here, we identify a senescent subset within previously-defined cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinomas (PDAC) and in premalignant lesions in mice and humans. Senescent CAFs isolated from mouse and humans expressed elevated levels of immune-regulatory genes. Depletion of senescent CAFs, either genetically or using the Bcl-2 inhibitor ABT-199 (venetoclax), increased the proportion of activated CD8+ T cells in mouse pancreatic carcinomas, whereas induction of CAF senescence had the opposite effect. Combining ABT-199 with an immune checkpoint therapy regimen significantly reduced mouse tumor burden. These results indicate that senescent CAFs in PDAC stroma limit the numbers of activated cytotoxic CD8+ T cells, and suggest that their targeted elimination through senolytic treatment may enhance immunotherapy.